热门资讯> 正文
Janux Therapeutics GAAP每股收益为-0.36美元,击败0.07美元
2025-02-28 06:40
- Janux Therapeutics press release (NASDAQ:JANX): Q4 GAAP EPS of -$0.36 beats by $0.07.
- Shares +1.53% AH.
More on Janux Therapeutics
- Janux Therapeutics: mCRPC TAM And Promising JANX007's Phase 1 Data
- Janux Therapeutics: Hype Breeds Volatility, And That Should Give You Pause
- Viking Therapeutics among potential buyout candidates: Oppenheimer
- Janux Therapeutics prices $350M securities offering
- Seeking Alpha’s Quant Rating on Janux Therapeutics
风险及免责提示:以上内容仅代表作者的个人立场和观点,不代表华盛的任何立场,华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前,应结合自身情况,考虑投资产品的风险。必要时,请咨询专业投资顾问的意见。华盛不提供任何投资建议,对此亦不做任何承诺和保证。